Treatment of naïve patients with chronic hepatitis c genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: Relevance for the new era of DAA

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Heidrich, Benjamin ^a,b,c   Wiegand, Steffen B ^a,b,c   Buggisch, Peter ^d   Hinrichsen, Holger ^e   Link, Ralph ^f   Möller, Bernd ^g   Böker, Klaus H W ^h   Teuber, Gerlinde ⁱ   Klinker, Hartwig ^j   Zehnter, Elmar ^k   Naumann, Uwe ^l   Busch, Heiner W ^m   Maasoumy, Benjamin ^a,b,c   Baum, Undine ^a,b,c   Hardtke, Svenja ^a,b,c   Manns, Michael P ^a,b,c   Wedemeyer, Heiner ^a,b,c   Petersen, Jörg ^d   Cornberg, Markus ^a,b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN RESEARCH FOUNDATION   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e Gastroenterology Gastroenterologische Schwerpunkt Praxis   (Germany)

^f St Josefs Hospital   (Germany)

^g Medical Practice   (Germany)

^h Leberpraxis   (Germany)

ⁱ Gastroenterology Practice   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k Private Practice   (Germany)

^l Center for Space Medicine   (Germany)

^m Medical Practice   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE REGISTRY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTOCOL COMPLIANCE; SHORT COURSE THERAPY; TREATMENT RESPONSE; AGED; CHEMISTRY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

HEPATITIS C VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; YOUNG ADULT;

EID: 84907830925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108751     Document Type: Article

References (21)

1. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, et al. (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int Off J Int Assoc Study Liver 31 Suppl 2: 30-60. doi:10.1111/j.1478-3231.2011.02539.x
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol Baltim Md 57: 1333-1342. doi:10.1002/hep.26141
3. Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26: 401-412. doi:10.1016/j.bpg.2012.09.009
4. Cornberg M, Deterding K, Manns MP (2006) Present and future therapy for hepatitis C virus. Expert Rev Anti Infect Ther 4: 781-793. doi:10.1586/14787210.4.5.781
5. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1: S88-S100. doi:10.1016/S0168-8278(12)60010-5
6. Dusheiko G, Wedemeyer H (2012) New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 61: 1647-1652. doi:10.1136/gutjnl-2012-302910
7. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878-1887. doi:10.1056/NEJMoa1214853.
8. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877. doi:10.1056/NEJMoa 1214854
9. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, et al. (2013) Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. Hepatol Baltim Md 58: 733A.
10. The price of good health (2014). Nat Med 20: 319. doi:10.1038/nm.3538
11. Hadziyannis SJ, Koskinas JS (2004) Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res Off J Jpn Soc Hepatol 29: 129-135. doi:10.1016/j.hepres.2004.02.011
12. Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, et al. (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522-527. doi:10.1016/j.gastro.2005.05.008
13. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, et al. (2008) Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatol Baltim Md 47: 35-42. doi:10.1002/hep.21975
14. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617. doi:10.1056/NEJMoa042608
15. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, et al. (2010) [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Für Gastroenterol 48: 289-351. doi:10.1055/s-0028-1110008
16. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128: 343-350.
17. AASLD (2014) Recommendations for Testing, Managing, and Treating Hepatitis C. Available: http://www.hcvguidelines.org/fullreport
18. European Association for Study of Liver (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60: 392-420. doi:10.1016/j.jhep.2013.11.003
19. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, et al. (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357: 124-134. doi:10.1056/NEJMoa066403
20. Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, et al. (2011) Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 55: 554-563. doi:10.1016/j.jhep.2010.12.024
21. Lawitz E, Poordad F, Brainard D, Hyland RH, An D, et al. (n.d.) Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. Hepatol Baltim Md 58: LB#4.